Top GSK/ViiV scientist who co-invented an HIV blockbuster books a trip to biotech

Brian A. Johns, a top HIV scientist at GSK’s ViiV, is following the well-traveled road into biotech.

Noted as a co-inventor of dolutegravir — a bestselling HIV drug marketed alone as Tivicay — as well as the long-acting cabotegravir, Johns was featured in PhRMA’s Go Boldly campaign celebrating the industry’s breakthrough successes and the people who made them happen. And now he’s joining HemoShear in Charlottesville, VA as their new CSO.